Evidence map›Paper›PMID 31318938›Full record

ArticlePloS one2019

Early treated HIV-infected children remain at risk of growth retardation during the first five years of life: Results from the ANRS-PEDIACAM cohort in Cameroon.

Casimir Ledoux Sofeu, Mathurin Cyrille Tejiokem, Calixte Ida Penda, Camelia Protopopescu, Francis Ateba Ndongo, Suzie Tetang Ndiang, Georgette Guemkam, Josiane Warszawski, Albert Faye, Roch Giorgi and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Casimir Ledoux SofeuCentre Pasteur du Cameroun, Service d'épidémiologie et de santé publique, Yaoundé, Cameroun.ORCID 0000-0002-4304-990X
Mathurin Cyrille TejiokemCentre Pasteur du Cameroun, Service d'épidémiologie et de santé publique, Yaoundé, Cameroun.
Calixte Ida PendaUniversité de Douala, Faculté de Médecine et de Sciences Pharmaceutiques, Cameroun.
Camelia ProtopopescuAix-Marseille Univiversité, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, France.
Francis Ateba NdongoCentre Mère et Enfant de la Fondation Chantal Biya, Yaoundé, Cameroun.
Suzie Tetang NdiangCentre Hospitalier d'Essos, Yaoundé, Cameroun.
Georgette GuemkamCentre Mère et Enfant de la Fondation Chantal Biya, Yaoundé, Cameroun.
Josiane WarszawskiINSERM U1018 (CESP)-Equipe 4 (VIH et IST), Le Kremlin Bicêtre, France.
Albert FayeAssistance Publique des Hôpitaux de Paris, Pédiatrie Générale, Hôpital Robert Debré, Paris, France.
Roch GiorgiAix-Marseille Univiversité, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, France.
ANRS-PEDIACAM study group
Inserm · FRCentre International De Reference Chantal Biya · CMCentre Pasteur du Cameroun · CMUniversité de Bordeaux · FRUniversité Paris-Sud · FRUniversity of Douala · CMUniversity Teaching Hospital of Yaounde · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term growth in HIV-infected infants treated early in resource-limited settings is poorly documented. Incidence of growth retardation, instantaneous risk of death related to malnutrition and growth parameters evolution during the first five years of life of uninfected and early treated HIV-infected children were compared and associated factors with growth retardation were identified.

methodsWeight-for-age (WAZ), weight-for-length (WLZ), and length-for-age (LAZ) Z-scores were calculated. The ANRS-PEDIACAM cohort includes four groups of infants with three enrolled during the first week of life: HIV-infected (HI, n = 69), HIV-exposed uninfected (HEU, n = 205) and HIV-unexposed uninfected (HUU, n = 196). The last group included HIV-infected infants diagnosed before 7 months of age (HIL, n = 141). The multi-state Markov model was used to describe the incidence of growth retardation and identified associated factors.

resultsDuring the first 5 years, 27.5% of children experienced underweight (WAZ<-2), 60.4% stunting (LAZ<-2) and 41.1% wasting (WLZ<-2) at least once. The instantaneous risk of death observed from underweight state (35.3 [14.1-88.2], 84.0 [25.5-276.3], and 6.0 [1.5-24.1] per 1000 person-months for 0-6 months, 6-12 months, and 12-60 months respectively) was higher than from non-underweight state (9.6 [5.7-16.1], 20.1 [10.3-39.4] and 0.3 [0.1-0.9] per 1000 person-months). Compared to HEU, HIL and HI children were most at risk of wasting (adjusted HR (aHR) = 4.3 (95%CI: 1.9-9.8), P<0.001 and aHR = 3.3 (95%CI: 1.4-7.9), P = 0.01 respectively) and stunting for HIL (aHR = 8.4 (95%CI: 2.4-29.7). The risk of underweight was higher in HEU compared to HUU children (aHR = 5.0 (CI: 1.4-10.0), P = 0.001). Others associated factors to growth retardation were chronic pathologies, small size at birth, diarrhea and CD4< 25%.

conclusionsHIV-infected children remained at high risk of wasting and stunting within the first 5 years period of follow-up. There is a need of identifying suitable nutritional support and best ways to integrate it with cART in pediatric HIV infection global care.

Indexed as

Antiretroviral Therapy, Highly ActiveCameroonCohort StudiesFemaleGrowth DisordersHIV InfectionsHumansIncidenceInfantInfant, NewbornMaleRisk AssessmentRisk FactorsTime-to-Treatment

Identifiers

PMID31318938
PMCPMC6638950
OpenAlexW2961797851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.